Results 1 to 10 of about 638,047 (318)

Prostate cancer

The Lancet, 2021
The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic landscape and biology underpinning both primary and metastatic prostate cancer. Similarly, the emergence of more sensitive imaging methods has improved diagnostic and staging accuracy and refined surveillance strategies ...
Sandhu, S, Moore, CM, Chiong, E, Beltran, H, Bristow, RG, Williams, SG   +5 more
  +11 more sources

Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition) [PDF]

Zhongguo aizheng zazhi, 2022
Metastatic hormone-sensitive prostate cancer (mHSPC) is a male health concern requiring continuous attention. In 2021, an important update was included in domestic and international guidelines regarding the recommendations of initial systemic therapy for
Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian
doaj   +1 more source

Examining the influence of illness perception and financial toxicity on the quality of life of prostate cancer patients

African Journal of Urology, 2021
Background Cancer of the prostate (CaP) is a public health problem that affects the male genitourinary system causing a significant threat to men’s quality of life (QoL).
Elizabeth O. Akin-Odanye, Chidiebere N. Ogo, Faoziyat A. Sulaiman, Lawal Suleiman, Motolani E. Ogunsanya, Folakemi T. Odedina   +5 more
doaj   +1 more source

Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes

BMC Urology, 2022
Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker   +11 more
doaj   +1 more source

The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer

BMC Urology, 2023
Purpose To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer (PCa), stratified according to Briganti ...
Paul Doan, Athos Katelaris, Matthijs J. Scheltema, Andrew Hayen, Amer Amin, Amila Siriwardana, Minh Tran, Bart Geboers, William Gondoputro, Anne Maree Haynes, Jayne Matthews, Warick Delprado, Phillip D. Stricker, James Thompson   +13 more
doaj   +1 more source

Prostate Cancer [PDF]

The Scientific World JOURNAL, 2011
Prostate cancer continues to be a significant public health issue worldwide, particularly in countries where men have life expectancies long enough to clinically manifest the disease. In many countries, it remains one of the leading causes of cancer-related morbidity and mortality.Although significant progress has been made over the past few decades ...
openaire   +3 more sources

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

The World Journal of Men's Health, 2023
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients.
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik   +15 more
doaj   +1 more source

Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells

Cancer Biology & Therapy, 2022
The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.
Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino   +10 more
doaj   +1 more source

HIF1 and ID1 Interplay Confers Adaptive Survival to HIF1α-Inhibition

Frontiers in Cell and Developmental Biology, 2021
Hypoxia is a universal pathological feature of solid tumors. Hypoxic tumor cells acquire metastatic and lethal phenotypes primarily through the activities of hypoxia-inducible factor 1 alpha (HIF1α).
Hao Geng, Hyun-Kyung Ko, Janet Pittsenbarger, Christopher T. Harvey, Changhui Xue, Qiong Liu, Sadie Wiens, Sushant K. Kachhap, Tomasz M. Beer, David Z. Qian   +9 more
doaj   +1 more source

Prostate cancer

Salud Pública de México, 2016
Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. Age and family history are the main risk factors. The diagnosis is made by prostate biopsy in patients with abnormalities detected in their prostate-specific antigen (PSA) levels or digital rectal exam (DRE).
Ricardo Alonso Castillejos-Molina, Fernando Bernardo Gabilondo-Navarro   +1 more
openaire   +5 more sources